Bollinger Band Squeeze Stocks
XFOR appears in our Bollinger Band Squeeze Stocks screen. This means the stock is showing a tight volatility setup, where the Bollinger Bands have narrowed and price may be preparing for a larger breakout move.
X4 PHARMACEUTICALS INC (XFOR) Stock Price & Overview
NASDAQ:XFOR • US98420X2027
Current stock price
4.13 USD
+0.03 (+0.73%)
Last:
The current stock price of XFOR is 4.13 USD. Today XFOR is up by 0.73%. In the past month the price decreased by -0.73%. In the past year, price increased by 10.07%.
XFOR Key Statistics
52-Week Range1.35 - 4.83
Current XFOR stock price positioned within its 52-week range.
1-Month Range3.7 - 4.66
Current XFOR stock price positioned within its 1-month range.
- Market Cap
- 375.5M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.34
- Dividend Yield
- N/A
XFOR Stock Performance
Today
+0.73%
1 Week
-7.24%
1 Month
-0.73%
3 Months
+10.81%
Longer-term
6 Months +1.49%
1 Year +10.07%
2 Years -87.80%
3 Years -90.70%
5 Years -98.37%
10 Years N/A
XFOR Stock Chart
XFOR Stock Screens
XFOR currently appears in the following ChartMill screener lists.
XFOR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to XFOR. When comparing the yearly performance of all stocks, XFOR turns out to be only a medium performer in the overall market: it outperformed 62.58% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
XFOR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XFOR. While XFOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
XFOR Earnings
On April 29, 2026 XFOR reported an EPS of -0.22 and a revenue of 2.57M. The company beat EPS expectations (37.93% surprise) and beat revenue expectations (45.25% surprise).
Next Earnings DateAug 6, 2026
Last Earnings DateApr 29, 2026
PeriodQ4 / 2025
EPS Reported-$0.22
Revenue Reported2.568M
EPS Surprise 37.93%
Revenue Surprise 45.25%
XFOR Forecast & Estimates
9 analysts have analysed XFOR and the average price target is 11.9 USD. This implies a price increase of 188.14% is expected in the next year compared to the current price of 4.13.
For the next year, analysts expect an EPS growth of 79.47% and a revenue growth -76.54% for XFOR
Analysts
Analysts86.67
Price Target11.9 (188.14%)
EPS Next Y79.47%
Revenue Next Year-76.54%
XFOR Financial Highlights
Over the last trailing twelve months XFOR reported a non-GAAP Earnings per Share(EPS) of -4.34. The EPS increased by 79.62% compared to the year before.
Income Statements
Revenue(TTM)35.11M
Net Income(TTM)-79.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.27% | ||
| ROE | -42.51% | ||
| Debt/Equity | 0.41 |
Chartmill High Growth Momentum
EPS Q2Q%96.33%
Sales Q2Q%79.08%
EPS 1Y (TTM)79.62%
Revenue 1Y (TTM)1273.21%
XFOR Ownership
Ownership
Inst Owners83.16%
Shares90.92M
Float83.85M
Ins Owners0.57%
Short Float %3.75%
Short Ratio6.29
XFOR Industry Overview
XFOR operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.6
- Average Fwd P/E
- 22.2
- Average Debt/Equity
- 2.2
XFOR Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.98 | 360.632B | ||
| AMGN | AMGEN INC | 15.28 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.94 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.05 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.81 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.27 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.74 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.67 | 25.03B | ||
| INCY | INCYTE CORP | 10.8 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XFOR
Company Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
IPO: 2017-11-16
X4 PHARMACEUTICALS INC
61 North Beacon Street, 4th Floor
Boston MASSACHUSETTS 02134 US
CEO: Paula Ragan
Employees: 45
Phone: 18575298300
X4 PHARMACEUTICALS INC / XFOR FAQ
What does X4 PHARMACEUTICALS INC do?
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
What is the current price of XFOR stock?
The current stock price of XFOR is 4.13 USD. The price increased by 0.73% in the last trading session.
Does X4 PHARMACEUTICALS INC pay dividends?
XFOR does not pay a dividend.
What is the ChartMill rating of X4 PHARMACEUTICALS INC stock?
XFOR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of X4 PHARMACEUTICALS INC (XFOR) based on its PE ratio?
X4 PHARMACEUTICALS INC (XFOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.34).
Can you provide the number of employees for X4 PHARMACEUTICALS INC?
X4 PHARMACEUTICALS INC (XFOR) currently has 45 employees.
What is X4 PHARMACEUTICALS INC worth?
X4 PHARMACEUTICALS INC (XFOR) has a market capitalization of 375.50M USD. This makes XFOR a Small Cap stock.